market access Archives -

NHS and Kite sign access deal for Kite’s cancer cell therapy Tecartus

https://pharmaphorum.com/news/nhs-kite-cancer-therapy/

NICE recommends interim funding for GSK’s Zejula in ovarian cancer

https://pharmaphorum.com/news/nice-recommends-interim-funding-for-gsks-zejula-in-ovarian-cancer/

2021 – UK market access prospects

https://pharmaphorum.com/views-analysis-market-access/2021-uk-market-access-prospects/

Unconvinced by NHS test run, NICE rejects BMS’ Opdivo in head and neck cancer

https://pharmaphorum.com/news/unconvinced-by-nhs-test-run-nice-rejects-bms-opdivo-in-head-and-neck-cancer/

Sanofi/GSK trial woes delay a billion COVID-19 shots by nine months

https://pharmaphorum.com/news/sanofi-gsk-trial-woes-delay-a-billion-covid-19-shots-by-nine-months/

CLL patients in England to get AZ’s Calquence after okay from NICE

https://pharmaphorum.com/news/cll-patients-in-england-to-get-azs-calquence-after-okay-from-nice/

The calm after the storm: How COVID-19 is making pharma more resilient

https://pharmaphorum.com/views-analysis-sales-marketing/the-calm-after-the-storm-how-covid19-is-making-pharma-more-resilient-and-accessible/

Gene Therapy Medical Affairs

https://pharmaphorum.com/events/gene-therapy-medical-affairs/

FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar

https://pharmaphorum.com/news/novartis-lucentis-could-face-biosimilar-competition/

Search